Vivos Therapeutics (NASDAQ: VVOS) furnishes Q2 2025 earnings press release

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Vivos Therapeutics, Inc. filed a current report to furnish a press release announcing its financial results for the second quarter ended June 30, 2025. The company issued this press release on August 19, 2025, and attached it as Exhibit 99.1.

The financial results and related details are contained in the press release, which is incorporated by reference but expressly treated as “furnished” rather than “filed” under the Exchange Act. The filing also includes an iXBRL cover page as Exhibit 104.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

08/20/2025 - 04:05 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 20, 2025 (August 19, 2025)

Vivos Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-39796	81-3224056
(State or other jurisdiction	(Commission	(I.R.S. Employer
of incorporation)	File Number)	Identification No.)

7921 Southpark Plaza, Suite 210

Littleton, Colorado 80120

(Address of principal executive offices) (Zip Code)

(844) 672-4357

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		VVOS		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 19, 2025, Vivos Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release of the Company, dated August 19, 2025 announcing its financial results for the second quarter ended June 30, 2025.
104		Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VIVOS THERAPEUTICS, INC.

Dated: August 20, 2025	By:	/s/ Bradford Amman
	Name:	Bradford Amman
	Title:	Chief Financial Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did Vivos Therapeutics (VVOS) disclose in this 8-K filing?

Vivos Therapeutics furnished a press release announcing its financial results for the second quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and provides the detailed financial information for that period.

Which period do the Vivos Therapeutics (VVOS) results in this filing cover?

The results relate to the company’s financial performance for the second quarter ended June 30, 2025. All detailed figures and commentary for that quarter are included in the press release furnished as Exhibit 99.1 to the report.

How are Vivos Therapeutics’ Q2 2025 results presented to investors in this 8-K?

The company’s Q2 2025 results are presented through a press release dated August 19, 2025. This release is furnished, not filed, as Exhibit 99.1 and is incorporated by reference for investors seeking the specific financial data.

Why does Vivos Therapeutics mark the Q2 2025 press release as furnished, not filed?

The company states the information in the report, including Exhibit 99.1, is furnished rather than filed under Section 18 of the Exchange Act. This treatment limits certain statutory liabilities associated with filed information while still making the results publicly available.

What exhibits are included with Vivos Therapeutics (VVOS) Q2 2025 8-K?

Two exhibits accompany the report: Exhibit 99.1, which is the press release announcing financial results for the quarter ended June 30, 2025, and Exhibit 104, which is the Inline XBRL-formatted cover page data file.